Literature DB >> 16868498

Prevalence of drug-resistance mutations and non-subtype B strains among HIV-infected infants from New York State.

Marine Karchava1, Wendy Pulver, Lou Smith, Sean Philpott, Timothy J Sullivan, Judith Wethers, Monica M Parker.   

Abstract

Prevalence studies indicate that transmission of drug-resistant HIV has been rising in the adult population, but data from the perinatally infected pediatric population are limited. In this retrospective study, we sequenced the pol region of HIV from perinatally infected infants diagnosed in New York State in 2001-2002. Analyses of drug resistance, subtype diversity, and perinatal antiretroviral exposure were conducted, and the results were compared with those from a previous study of HIV-infected infants identified in 1998-1999. Eight of 42 infants (19.1%) had provirus carrying at least 1 drug-resistance mutation, an increase of 58% over the 1998-1999 results. Mutations conferring resistance to nucleoside reverse transcriptase inhibitors, nonnucleoside reverse transcriptase inhibitors, and protease inhibitors were detected in 7.1%, 11.9%, and 2.4% of specimens, respectively. Consistent with previous results, perinatal antiretroviral exposure was not associated with drug resistance (P = 0.70). Phylogenetic analysis indicated that 16.7% of infants were infected with a non-subtype B strain of HIV. It seems that drug-resistant and non-subtype B strains of HIV are becoming increasingly common in the perinatally infected population. Our results highlight the value of resistance testing for all HIV-infected infants upon diagnosis and the need to consider subtype diversity in diagnostic and treatment strategies.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16868498      PMCID: PMC2925654          DOI: 10.1097/01.qai.0000225871.87456.e7

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr        ISSN: 1525-4135            Impact factor:   3.731


  29 in total

1.  Genotype resistance profiles in patients failing an NNRTI-containing regimen, and modifications after stopping NNRTI therapy.

Authors:  Eugenia Quiros-Roldan; Monica Airoldi; Francesca Moretti; Caterina Fausti; Angelo Pan; Salvatore Casari; Carlo Torti; Francesco Castelli; Giampiero Carosi
Journal:  J Clin Lab Anal       Date:  2002       Impact factor: 2.352

2.  Evolving patterns of HIV-1 resistance to antiretroviral agents in newly infected individuals.

Authors:  Viviana Simon; Jeroen Vanderhoeven; Arlene Hurley; Bharat Ramratnam; Michael Louie; Keith Dawson; Neil Parkin; Daniel Boden; Martin Markowitz
Journal:  AIDS       Date:  2002-07-26       Impact factor: 4.177

3.  Virological and immunological effects of treatment interruptions in HIV-1 infected patients with treatment failure.

Authors:  V Miller; C Sabin; K Hertogs; S Bloor; J Martinez-Picado; R D'Aquila; B Larder; T Lutz; P Gute; E Weidmann; H Rabenau; A Phillips; S Staszewski
Journal:  AIDS       Date:  2000-12-22       Impact factor: 4.177

4.  Primary genotypic and phenotypic HIV-1 drug resistance in recent seroconverters in Madrid.

Authors:  C Briones; M Pérez-Olmeda; C Rodríguez; J del Romero; K Hertogs; V Soriano
Journal:  J Acquir Immune Defic Syndr       Date:  2001-02-01       Impact factor: 3.731

5.  Prevalence of genotypic drug resistance among a cohort of HIV-infected newborns.

Authors:  Monica M Parker; Nancy Wade; Robert M Lloyd; Guthrie S Birkhead; Brian K Gallagher; Babu Cheku; Timothy Sullivan; Jill Taylor
Journal:  J Acquir Immune Defic Syndr       Date:  2003-03-01       Impact factor: 3.731

6.  Persistence and fitness of multidrug-resistant human immunodeficiency virus type 1 acquired in primary infection.

Authors:  Bluma G Brenner; Jean-Pierre Routy; Marco Petrella; Daniela Moisi; Maureen Oliveira; Mervi Detorio; Bonnie Spira; Vidal Essabag; Brian Conway; Richard Lalonde; Rafick-Pierre Sekaly; Mark A Wainberg
Journal:  J Virol       Date:  2002-02       Impact factor: 5.103

7.  False negative DNA polymerase chain reaction in an infant with subtype C human immunodeficiency virus 1 infection.

Authors:  Nancy E Kline; Heidi Schwarzwald; Mark W Kline
Journal:  Pediatr Infect Dis J       Date:  2002-09       Impact factor: 2.129

8.  Antiretroviral-drug resistance among patients recently infected with HIV.

Authors:  Susan J Little; Sarah Holte; Jean-Pierre Routy; Eric S Daar; Marty Markowitz; Ann C Collier; Richard A Koup; John W Mellors; Elizabeth Connick; Brian Conway; Michael Kilby; Lei Wang; Jeannette M Whitcomb; Nicholas S Hellmann; Douglas D Richman
Journal:  N Engl J Med       Date:  2002-08-08       Impact factor: 91.245

9.  Nonnucleoside reverse transcriptase inhibitor resistance among antiretroviral-naive HIV-positive pregnant women.

Authors:  Salome N Juethner; Catherine Williamson; Maria B Ristig; Pablo Tebas; Warren Seyfried; Judith A Aberg
Journal:  J Acquir Immune Defic Syndr       Date:  2003-02-01       Impact factor: 3.731

10.  Time trends in primary HIV-1 drug resistance among recently infected persons.

Authors:  Robert M Grant; Frederick M Hecht; Maria Warmerdam; Lea Liu; Teri Liegler; Christos J Petropoulos; Nicholas S Hellmann; Margaret Chesney; Michael P Busch; James O Kahn
Journal:  JAMA       Date:  2002-07-10       Impact factor: 56.272

View more
  11 in total

1.  HIV-1 drug resistance at antiretroviral treatment initiation in children previously exposed to single-dose nevirapine.

Authors:  Gillian M Hunt; Ashraf Coovadia; Elaine J Abrams; Gayle Sherman; Tammy Meyers; Lynn Morris; Louise Kuhn
Journal:  AIDS       Date:  2011-07-31       Impact factor: 4.177

2.  Antiretroviral treatment failure, drug resistance, and subtype diversity in the only pediatric HIV clinic in Rhode Island.

Authors:  Tanya Rogo; Allison K DeLong; Philip Chan; Rami Kantor
Journal:  Clin Infect Dis       Date:  2015-01-30       Impact factor: 9.079

3.  Perinatal acquisition of drug-resistant HIV-1 infection: mechanisms and long-term outcome.

Authors:  Constance Delaugerre; Marie-Laure Chaix; Stephane Blanche; Josiane Warszawski; Dorine Cornet; Catherine Dollfus; Veronique Schneider; Marianne Burgard; Albert Faye; Laurent Mandelbrot; Roland Tubiana; Christine Rouzioux
Journal:  Retrovirology       Date:  2009-09-19       Impact factor: 4.602

4.  Phylogenetic and geospatial evaluation of HIV-1 subtype diversity at the largest HIV center in Rhode Island.

Authors:  Philip A Chan; Marissa B Reitsma; Allison DeLong; Bruce Boucek; Amy Nunn; Marco Salemi; Rami Kantor
Journal:  Infect Genet Evol       Date:  2014-04-08       Impact factor: 3.342

5.  Large-scale analysis of the prevalence and geographic distribution of HIV-1 non-B variants in the United States.

Authors:  Michael T Pyne; John Hackett; Vera Holzmayer; David R Hillyard
Journal:  J Clin Microbiol       Date:  2013-06-12       Impact factor: 5.948

6.  Cross-subtype detection of HIV-1 using reverse transcription and recombinase polymerase amplification.

Authors:  Lorraine Lillis; Dara A Lehman; Joshua B Siverson; Julie Weis; Jason Cantera; Mathew Parker; Olaf Piepenburg; Julie Overbaugh; David S Boyle
Journal:  J Virol Methods       Date:  2016-01-25       Impact factor: 2.014

7.  HIV Drug Resistance-Associated Mutations in Antiretroviral Naïve HIV-1-Infected Latin American Children.

Authors:  Luis E Soto-Ramirez; Roberto Rodriguez-Diaz; D Robert Harris; Rohan Hazra
Journal:  Adv Virol       Date:  2011-01-18

8.  Pregnancy in women with perinatally acquired HIV-infection: outcomes and challenges.

Authors:  Usha K Phillips; Michael G Rosenberg; Joanna Dobroszycki; Mindy Katz; Jorge Sansary; Mindy A Golatt; Andrew A Wiznia; Jacobo Abadi
Journal:  AIDS Care       Date:  2011-05-23

9.  Factors associated with HIV RNA levels in pregnant women on non-suppressive highly active antiretroviral therapy at conception.

Authors: 
Journal:  Antivir Ther       Date:  2010

10.  High drug resistance prevalence among vertically HIV-infected patients transferred from pediatric care to adult units in Spain.

Authors:  Miguel de Mulder; Gonzalo Yebra; Adriana Navas; María Isabel de José; María Dolores Gurbindo; María Isabel González-Tomé; María José Mellado; Jesús Saavedra-Lozano; María Ángeles Muñoz-Fernández; Santiago Jiménez de Ory; José Tomás Ramos; Africa Holguín
Journal:  PLoS One       Date:  2012-12-17       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.